An investigation on the anti-tumor properties of FSH-Lytic.

A new designed hybrid peptide FSH-Lytic was synthesized and expected to combine the follicle stimulating hormone receptor (FSHR) targeting and tumor cell membranes disintegration. Through in vitro and vivo study, no significant enhancement on anti-tumor activity was shown compared with Lytic peptide only. We also prepared F-Al-NOTA-MAL-FSH-Lytic and use microPET image to observe the FSHR targeting of FSH-Lytic. No accumulation in the tumor may explain the failure of FSH-Lytic on cancer therapy. In summary, microPET image can provide more accurate and visible information for screening new anti-tumor agents. [ABSTRACT FROM AUTHOR]